A KFF analysis shows that gross total Medicare spending on Ozempic and other similar drugs has increased dramatically in recent years – even though Medicare is explicitly prohibited by law from covering the drugs for obesity. That’s because Medicare now covers the drugs, known as GLP-1s, for other medically accepted indications, including to treat diabetes.…More
Related Articles
Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin
Kura Oncology already had a broad development plan for ziftomenib in leukemias,...
How Much More Would People Pay in Premiums if the ACA’s Enhanced Subsidies Expired?
Enhanced Affordable Care Act (ACA) subsidies lower premium payments for ACA Marketplace...
Everything You Need to Know About Hip Replacement Surgery in India
Hip replacement surgery is one of the most common and successful medical...
Speculation on RFK Jr. as HHS Secretary
From Tyler Cowen at Marginal Revolution: One of the problems with an...
Leave a comment